Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics

To evaluate the response to Tezepelumab in real clinical practice, we performed an analysis of the clinical, functional, and inflammatory characteristics of 13 patients with severe asthma after completing four doses of Tezepelumab was performed. When comparing clinical parameters such as asthma cont...

Full description

Saved in:
Bibliographic Details
Published in:Allergologia et immunopathologia 2024-01, Vol.52 (6), p.76-78
Main Authors: Betancor, Diana, Bautista, Sara, López-Rodríguez, Raquel, Valverde-Monge, Marcela, Fernández-Nieto, Mar, Rial, Manuel J
Format: Article
Language:English
Subjects:
Adult
Aged
Anti-Asthmatic Agents - administration & dosage
Anti-Asthmatic Agents - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - therapeutic use
Asthma
Asthma - diagnosis
Asthma - drug therapy
Asthma - immunology
Biological products
Biological Products - administration & dosage
Biological Products - therapeutic use
Biomarkers
Eosinophils - drug effects
Eosinophils - immunology
Female
Humans
Male
Middle Aged
Nitric Oxide - metabolism
Patients
Quality of life
Respiratory Function Tests
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the response to Tezepelumab in real clinical practice, we performed an analysis of the clinical, functional, and inflammatory characteristics of 13 patients with severe asthma after completing four doses of Tezepelumab was performed. When comparing clinical parameters such as asthma control test (ACT), FENO value, exacerbations in the last 4 months, blood eosinophils and FEV1%, before receiving Tezepelumab and after four doses of Tezepelumab, statistically significant differences were found in ACT levels (p=0.0072), exacerbations (p=0.018) and FEV1% (p=0.012) before and after four doses of Tezepelumab. No statistically significant differences were found in blood eosinophils or FeNO levels, however, a mean reduction of 102.5±231 cells/mm and 14.67±30 ppb, respectively, was observed. Patients with a high T2 profile had significantly higher baseline FeNO (p0.05). We demonstrated, in a multicenter study, the clinical improvement associated with tezepelumab treatment in severe uncontrolled asthma, independent of inflammatory biomarkers, eosinophilic profile, or previous biological failure.
ISSN:0301-0546
1578-1267
1578-1267
0301-0546
DOI:10.15586/aei.v52i6.1161